Merz Pharma Gmbh & Co Kgaa

Galimedix Therapeutics Inc.

Markus Henrich

Wojciech Danysz

Valerjans Kauss

Ivars Kalvinsh

Christopher Graham Raphael Parsons

Aigars Jirgensons

Tanja Weil

Maksims Vanejevs

Jens Nagel

Markus R Gold

Claudia Jatzke

Aleksandrs Gutcaits

Ieva Jaunzeme

Ronalds Zemribo

Juris Fotins

Andrzej Dekundy

Mirko Hechenberger

Herbert Koller

Michael Pyerin

Hermann Kurt Russ

Christopher G R Parsons

Igors Starchenkovs

Dina Trifanova

Jevgenijs Rozhkovs

Meik Sladek

Angela Bauer

Pal Kocsan

Gergely Tasi

Simona Negura

Pál KOCSÁN

Aleksandra Gutcaits

This intention relates to a novel polymorph form of compound (R)-2-[2-amino-3-(indol-3-yl)propionylamino]-2-methylpropionic acid, a process for making the novel polymorph form of the compound, and uses thereof for making other polymorph forms of the compound. The invention further relates to composition comprising novel polymorph form of the compound and a pharmaceutically acceptable carrier or excipient.

Polymorph form of (r)-2-[2-amino-3-(indol-3-yl)propionylamino]-2- methylpropionic acid and uses thereof

Process for manufacturing 1-amino-1,3,3,5,5-pentamethylcyclohexane mesylate comprising step (i):

Synthesis of 1-amino-1,3,3,5,5,-cyclohexane mesylate

The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.

Glycine B antagonist

Substituted pyrazolopyrimidine derivatives of formula (I) wherein

Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators

The invention relates to pyrazolopyrimidine derivatives of formula (I) wherein

Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators

The invention relates to tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR antagonists and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.

Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors

The invention relates to ethynyl-substituted tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.

Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors

Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borne virus, anti-HSV and anti-Hepatitis C virus activity.

[object Object]

Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.

Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists

Unsaturated 1-Amino-alkylcyclohexane compounds which are systemically-active as NMDA, 5HT , and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.

Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists

Growing community of inventors

Munzenberg, Germany

Markus Henrich